ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CVKD / forecast
MDCX (34) RDHL (52) GRI (34) ONCO (30) ⌘ Pro Terminal →

Cadrenal Therapeutics Inc. (CVKD) 12-Month Stock Forecast & Price Target Cone

$1.04 +5.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.05

Cadrenal Therapeutics Inc. (CVKD) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CVKD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CVKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cadrenal Therapeutics Inc. (NASDAQ: CVKD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.04 (+5.58% 1D, market cap $3.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CVKD ranks #661 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CVKD compare to MDCX and RDHL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CVKD carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MDCX (Medicus Pharma Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.6M) and RDHL (Redhill Biopharma Ltd.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $3.4M). Among the 5-stock peer group, CVKD leads on earnings multiple (N/A) while CVKD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CVKD?
▼

Per CVKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001937993), Cadrenal Therapeutics Inc. generated $37.7M in revenue (+22.8% YoY), -$13.2M in net income, and -$12.6M in free cash flow against $4.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.05 (+0.81%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (5)Whales (5)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.6% Base Target
$14 Bull$1 Base$1 Bear
📬 FREE CVKD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CVKD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY CVKD SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 46.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$1.00+4% Next Q
Q2 (-2Q)
29
Grade E$1.04-9.6% Next Q
Q3 (-1Q)
31
Grade E$0.94+10.6% Next Q
Current
34
Grade E$1.04-8.7% Hist 90D α
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CVKD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CVKD currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.12) and Max Pain ($1.09) forces dealer call-delta covering toward $14.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CVKD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CVKD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CVKD Position Size: $10,000

Shares at $1.04: 9615.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.73
$7,019
$-2,981 (-29.8%)
12M Consensus BaseTarget $0.93
$8,942
$-1,058 (-10.6%)
12M Bull Case BreakoutTarget $14.31
$137,596
+$127,596 (+1276.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1369%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CVKD)

  • ✓Walkthrough of CVKD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CVKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.27%▲ RESISTANCE BREAKOUT
2026-11-03O $0.95H $1.04L $0.95C $1.04VOL 80.7K
RES: $0.88SUP: $0.09SMA50: $1.12SMA200: $3.87
$10.19$7.65$5.11$2.57$0.03RES $0.88SUP $0.09$1.042026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CVKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CVKD Butterfly Map → + Track CVKD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +22.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CVKD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CVKD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CVKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CVKD)

Health Care Rank #661 of 1015 ⚔️ MDCX vs CVKD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CVKD vs. MDCX, RDHL, GRI, ONCO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cadrenal Therapeutics Inc. (CVKD) ranks #661 by composite RQD confidence (34/100, grade E) and #966 by equity capitalization ($3.5M). Within this direct 5-issuer industry benchmark cohort, CVKD leads on earnings valuation at N/A trailing P/E, while CVKD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RDHL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CVKD at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CVKD ACTIVE
Cadrenal Therapeutics Inc.
E 34/100 — — -35.0% +5.58% $3.5M Benchmark Subject
MDCX
Medicus Pharma Ltd.
E 34/100 — — -35.0% +2.66% $3.6M /mdcx-vs-cvkd →
RDHL
Redhill Biopharma Ltd.
D+ 52/100 — — — +13.87% $3.4M /rdhl-vs-cvkd →
GRI
GRI Bio Inc.
E 34/100 — — -35.0% -4.57% $3.3M /gri-vs-cvkd →
ONCO
Onconetix Inc.
E 30/100 — 77.6% -35.0% -3.24% $3.3M /onco-vs-cvkd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001937993 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cadrenal Therapeutics Inc. (CVKD) reported GAAP revenue of $37.7M (+22.8% vs. FY2024 revenue of $30.7M , and +76.4% cumulative change since FY2023) , GAAP net income of -$13.2M, operating cash flow of -$12.6M, and free cash flow of -$12.6M (-71.2% YoY). On the balance sheet, CVKD closed FY2025 with $4.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $37.7M -$13.2M -$12.6M -$12.6M $4.3M —
FY2024 (FY) 2024-12-31 $30.7M -$10.7M -$7.4M -$7.4M $10.1M —
FY2023 (FY) 2023-12-31 $21.4M -$8.4M -$3.5M -$3.5M — —

3. CVKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CVKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cadrenal Therapeutics Inc. (NASDAQ: CVKD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.04 (+5.58% 1D, market cap $3.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CVKD ranks #661 in composite RQD confidence.

How does CVKD compare to MDCX and RDHL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CVKD carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MDCX (Medicus Pharma Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.6M) and RDHL (Redhill Biopharma Ltd.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $3.4M). Among the 5-stock peer group, CVKD leads on earnings multiple (N/A) while CVKD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CVKD?

Per CVKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001937993), Cadrenal Therapeutics Inc. generated $37.7M in revenue (+22.8% YoY), -$13.2M in net income, and -$12.6M in free cash flow against $4.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CVKD trading relative to its 50-day, 200-day, and 52-week technical levels?

CVKD last traded at $1.04 (+5.58% on volume of 284,881 shares), positioning the stock -7.14% below its 50-day simple moving average ($1.12) and -73.13% below its 200-day simple moving average ($3.87). Across its 52-week range of $0.82 to $13.63, CVKD sits at the 1.7% percentile with a 14-day RSI of 46.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.17).

Direct Sub-Reports: CVKD RQD Cockpit CVKD 12M Forecast CVKD Earnings & Move CVKD Dividends & DRIP CVKD Insiders & 13F CVKD Whale Options CVKD Profit Sankey CVKD News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

CVKD — Cadrenal Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cadrenal Therapeutics Inc. (CVKD) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.04 (+5.58% 1D, market capitalization $3.5M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cadrenal Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Reported revenue is — across the FY 2023 through FY 2025 periods (), which indicates the company is not currently generating product or service revenue in the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cadrenal Therapeutics Inc. (CVKD) reported $37.7M in annual revenue (up from $30.7M in FY2024, +22.8% YoY) and -$13.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($21.4M revenue, -$8.4M net income) through FY2025, CVKD scaled operating cash flow to -$12.6M and free cash flow to -$12.6M, backed by $4.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.82 – $13.63 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification. A prospective investor should note that the absence of mapped links means the source cannot quantify ripple effects from partner deals, supplier dependencies, or competitor developments.

  • Key Question #1: Can CVKD sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $37.7M and free cash flow of -$12.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CVKD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CVKD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cadrenal Therapeutics Inc. (CVKD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CVKD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CVKD Bull vs. Bear Conversation Board — What's Your Call at $1.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CVKD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CVKD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $1.31 (+32.3%)
📌 Pinned Debate

Potential partners have shown strong interest and the company is evaluating possible deals.

Long CVKD at $0.99 targeting $1.31. Potential partners have shown strong interest and the company is evaluating possible deals.. Institutional whale score is 5/20 and the risk/reward vs. the $0.82 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — CVKD's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.77 (-22.2%)
Spot @ $0.99

The company reports zero revenue, a -35% ROIC, and a cash balance that fell from $10.0M to $4.0M over two years.

I respect the product at Cadrenal Therapeutics Inc., but the stock at $0.99 is a different story. The company reports zero revenue, a -35% ROIC, and a cash balance that fell from $10.0M to $4.0M over two years.. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE